Status:

COMPLETED

Evaluation of Accuracy of CFD-based RuiXin-FFR by Comparing With Pressure-wire-based FFR

Lead Sponsor:

Beijing Anzhen Hospital

Conditions:

Coronary Artery Disease

Myocardial Ischemia

Eligibility:

All Genders

18+ years

Brief Summary

Coronary Artery Disease (CAD) is the top killer nowadays. Pressure-wire-based Fractional Flow Reserve (FFR) is the gold standard for measuring ischemia in coronary arteries. CFD-based RuiXin-FFR, whic...

Detailed Description

The participants are entered with suspended CAD and angiography ischemia between 30%-90% from 6 hospitals in China. Pressure-wire-based FFR is conducted in the standard protocol by each hospital. FFR\...

Eligibility Criteria

Inclusion

  • able to understand the purpose of the study and sign the informed consent
  • with diagnosed or confirmed coronary artery disease according to the comprehensive clinical assessment
  • with CTA image indicating that the diameter of the reference vessel in the stenosis segment was ≥2mm
  • with CTA image indicating that the stenosis degree of coronary artery lumen diameter ≥30% and ≤90%

Exclusion

  • prior coronary artery bypass bypass (CABG) surgery, coronary interventional therapy (PCI), artificial heart valve implantation, cardiac pacemaker or implantable defibrillator implantation
  • persistent or active symptoms of clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure status (systolic pressure less than 90 mmHg), severe congestive heart failure (NYHA grade III or IV), or acute pulmonary edema
  • acute myocardial infarction occurred within 7 days before inclusion
  • complex congenital heart disease, sick sinus syndrome, long QT syndrome, severe arrhythmia, tachycardia, severe asthma, severe or very severe chronic obstructive pulmonary disease (COPD) and chronic renal damage (serum creatinine value \> 1.5 mg/dl or creatinine clearance \< 45 ml/Kg\*1.73 m2)
  • there are contraindications for the use of adenosine disodium triphosphate
  • allergic to iodized contrast media
  • pregnancy or pregnancy status unknown
  • life expectancy less than 2 months
  • there are any factors that other researchers consider not suitable for inclusion or completion of this study
  • obvious mismatch of coronary artery CTA images
  • CTA image showing calcification occupies the cross-sectional area of the lumen \> 80%
  • CT value standard deviation of aortic root image \>30HU
  • coronary artery occlusion.

Key Trial Info

Start Date :

March 13 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 31 2020

Estimated Enrollment :

316 Patients enrolled

Trial Details

Trial ID

NCT04731285

Start Date

March 13 2019

End Date

August 31 2020

Last Update

September 5 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Shaoping Nie

Beijing, China